Brightening routines built for lighter skin tones do not translate directly to melanin-rich skin — and applying them uncritically can make things worse. The core issue is that darker skin tones have more reactive melanocytes: they produce more melanin in response to the same inflammatory signal, and they are more likely to develop post-inflammatory hyperpigmentation from the very ingredients meant to address it. High-concentration glycolic acid at low pH, kojic acid at irritating doses, and aggressive exfoliation schedules can all trigger more PIH in dark skin than they resolve. Building the right brightening routine for Fitzpatrick III–VI skin requires knowing which actives have the best safety and efficacy profile specifically for this context — not the general brightening context.
The safest and most effective brightening stack for melanin-rich skin: azelaic acid (tyrosinase inhibitor, anti-inflammatory, no irritation-driven PIH risk), tranexamic acid (targets the PIH mechanism directly), niacinamide (inhibits melanosome transfer, barrier support), and mandelic acid for gentle exfoliation (gentler than glycolic, antibacterial benefit for acne-PIH). SPF 50 daily is non-negotiable — UV is the most powerful PIH trigger and the most powerful barrier to clearing it. Avoid: high-concentration glycolic at low pH (irritation risk), kojic acid without careful dose management, retinoids introduced too quickly (purging in dark skin produces more PIH than in lighter skin).
Not all dark marks respond to the same treatment, and melanin-rich skin is particularly susceptible to multiple distinct types simultaneously. Correctly identifying which type you are dealing with determines which ingredients will work and which timeline to expect.
Post-inflammatory hyperpigmentation (PIH) is the most common — flat, brown to grey-brown marks left at the site of healed acne, eczema, or any other inflammatory lesion. It is caused by melanocyte overactivation in response to the inflammatory signal. PIH can be epidermal (brown, responds well to topical treatment) or dermal (grey-blue, much slower to respond, sometimes requires professional intervention). The grey cast of dermal PIH is the result of melanin being trapped in the dermis rather than distributed through the epidermis.
Melasma presents as larger, more diffuse patches of hyperpigmentation — typically symmetric, often on the cheeks, forehead, and upper lip. It is driven by a combination of UV, visible light, heat, and hormonal triggers (particularly oestrogen and progesterone). It has a dermal component in many cases that makes it significantly harder to treat than epidermal PIH. UV and visible light protection are critical — and unlike PIH, melasma will persistently recur if triggers are not managed, even after successful treatment. Tinted mineral sunscreens with iron oxides are specifically important for melasma because iron oxides partially attenuate visible light, which is a melasma trigger that standard SPF does not block. See our hyperpigmentation vs melasma guide for the full clinical distinction.
Periorbital hyperpigmentation (dark circles) has multiple causes in darker skin — vascular (visible vessels), structural (shadowing from anatomical features), and pigmentary (true melanin deposits in the periorbital area). The pigmentary type responds to the same brightening actives as PIH; the vascular type does not. Understanding which is driving the appearance is important before committing to a brightening protocol for the under-eye area.
One of the most common points of frustration with brightening routines is unrealistic timelines — people expect results in two weeks and abandon a protocol that would have worked at twelve. For melanin-rich skin specifically, the timeline is longer than generic brightening content suggests, for two reasons: the melanocytes are more reactive (producing more pigment per inflammatory trigger), and the skin needs a more conservative active introduction approach that adds time to the protocol.
Realistic timelines for a consistent evidence-based protocol (azelaic acid + tranexamic acid + niacinamide + SPF, used daily):
The single variable that most powerfully affects this timeline is SPF compliance. In a study by Grimes (2009), patients using the same brightening actives with consistent SPF50 cleared PIH in approximately half the time of patients using actives without consistent sun protection. UV is continuously re-triggering melanocyte activation and undoing the tyrosinase inhibition — without SPF, the brightening actives are fighting a battle on two fronts simultaneously.
Melanocytes in Fitzpatrick III–VI skin are not more numerous than in lighter skin — the difference is in their activity level and reactivity. They produce larger, more densely packed melanosomes, and they respond to inflammatory signals with a more vigorous melanin production increase. This means any ingredient or approach that causes irritation — even mild irritation that would be subclinical in lighter skin — can trigger new PIH in darker skin. This is the fundamental tension in brightening for darker skin tones: many brightening actives work partly through irritation or cell turnover stimulation that carries a paradoxical PIH risk.
The strategy is to select actives that address melanin production or transfer through targeted biological mechanisms rather than through irritation-driven effects — and to be more conservative with exfoliation frequency and concentration than general recommendations suggest.
Azelaic acid is consistently recommended by dermatologists specialising in skin of colour as the first-line topical for PIH. Its tyrosinase inhibition selectively targets hyperactive melanocytes — normal melanocytes are affected less — which means it brightens PIH without causing paradoxical lightening of surrounding normal skin. It is simultaneously anti-inflammatory (reducing the inflammatory signal that triggers melanocyte overactivation in the first place) and antibacterial, making it double-useful for acne-PIH cycles. At 10% OTC or 15–20% prescription, it has an excellent tolerability profile in all skin tones including darker. It does not cause the irritation-driven PIH risk that higher-potency tyrosinase inhibitors carry.
Tranexamic acid blocks the plasmin-mediated keratinocyte-melanocyte cross-talk that drives post-inflammatory melanin overproduction. Rather than simply inhibiting tyrosinase after melanin production has been triggered, tranexamic acid interrupts the signalling cascade earlier — preventing the melanocyte from receiving the overproduction signal in the first place. This makes it uniquely suited for PIH, particularly in skin that generates PIH easily. Clinical evidence specifically in Asian and darker skin tones shows significant efficacy with minimal irritation. Use AM, combined with niacinamide.
Niacinamide inhibits the transfer of melanosomes (melanin-containing vesicles) from melanocytes into surrounding keratinocytes — reducing the amount of melanin that actually reaches the skin surface even when melanocyte production is not reduced. It has separate evidence for reducing the appearance of existing hyperpigmentation over 8–12 weeks. It also strengthens the barrier, which reduces the irritation-triggered melanocyte activation that perpetuates PIH. Non-irritating, barrier-supportive, and compatible with everything. This is a daily AM and PM ingredient.
Exfoliation accelerates PIH clearance by removing pigmented surface cells faster than passive desquamation. The choice of exfoliant matters significantly for darker skin. Mandelic acid is the preferred AHA — its larger molecular size means slower, more superficial penetration than glycolic acid, dramatically reducing the irritation and inflammation risk that can trigger new PIH. It also has mild antibacterial activity useful in acne-PIH skin. Use 2× per week PM, not on the same nights as retinoids, and never at the same time as azelaic acid (space them across different nights). High-concentration glycolic acid (10%+) at low pH should be avoided or used with extreme caution — it penetrates aggressively and its irritation potential in darker skin is well-documented in dermatology literature as a PIH trigger.
Retinoids are useful for brightening — they accelerate cell turnover and clear pigmented cells, and they prevent new PIH formation by normalising the keratinocyte cycle. But the purging and adjustment phase in darker skin can produce significant new PIH if introduction is too aggressive. The protocol for darker skin: start at the lowest available concentration (retinol 0.025% or adapalene 0.1%), use once per week for the first month, build to every other night over 3–4 months minimum. The retinol introduction guide protocol applies, but with an even more conservative timeline. During purging, the niacinamide + tranexamic acid AM stack is doing preventive work on any new PIH the purging process generates.
| Step | AM | PM |
|---|---|---|
| Cleanse | Gentle, fragrance-free, pH-balanced | Same; double cleanse if wearing SPF/makeup |
| Active 1 | Tranexamic acid serum | Azelaic acid 10% (alternate with mandelic 2×/week) |
| Active 2 | Niacinamide serum | Niacinamide serum |
| Retinoid | — | Retinol (every 3rd night, building slowly over months) |
| Moisturise | Ceramide-rich, fragrance-free | Same or richer |
| SPF | Broad-spectrum SPF 50 — chemical formula preferred for no white cast | — |
Build and verify this routine in the Skin Stacker Routine Builder. For the companion article on sunscreen selection for darker skin tones, see our sunscreen for dark skin tones guide. For the PIH science, see our hyperpigmentation vs melasma guide.